IL-33 biology in cancer: An update and future perspectives.

Yeoh, Wen Jie; Vu, Vivian P; Krebs, Philippe (2022). IL-33 biology in cancer: An update and future perspectives. Cytokine, 157, p. 155961. Elsevier 10.1016/j.cyto.2022.155961

Preview

Text 1-s2.0-S1043466622001703-main.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (3MB) | Preview

Interleukin-33 (IL-33) is a member of the IL-1 family of cytokines that is constitutively expressed in the nucleus of epithelial, endothelial and fibroblast-like cells. Upon cell stress, damage or necrosis, IL-33 is released into the cytoplasm to exert its prime role as an alarmin by binding to its specific receptor moiety, ST2. IL-33 exhibits pleiotropic function in inflammatory diseases and particularly in cancer. IL-33 may play a dual role as both a pro-tumorigenic and anti-tumorigenic cytokine, dependent on tumor and cellular context, expression levels, bioactivity and the nature of the inflammatory environment. In this review, we discuss the differential contribution of IL-33 to malignant or inflammatory conditions, its multifaceted effects on the tumor microenvironment, while providing possible explanations for the discrepant findings described in the literature. Additionally, we examine the emerging and divergent functions of IL-33 in the nucleus, and aspects of IL-33 biology that are currently under-addressed.

Interest & Impact

Downloads

152 since deposited on 20 Jul 2022
92 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item